Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

Lung & thoracic cancers


Breaking news, expert video interviews, and educational materials for healthcare professionals managing thoracic cancer patients.


Highlights

06-06-2023 | Non-small-cell lung cancer | Conference coverage | News

ADAURA demonstrates OS gain with adjuvant osimertinib in early-stage NSCLC

Adjuvant treatment with osimertinib significantly prolongs overall survival relative to placebo in people with EGFR-mutated, early-stage non-small-cell lung cancer, show trial results.

28-10-2022 | Non-small-cell lung cancer | News

Real-world study adds support for osimertinib for uncommon EGFR mutations

Osimertinib elicits high rates of systemic and intracranial response in people with advanced non-small-cell lung cancer harboring uncommon EGFR mutations, say the authors of the real-world UNICORN study.

12-10-2022 | Small-cell lung cancer | News

First-line serplulimab plus chemo improves extensive-stage SCLC survival

The addition of the anti-PD-1 agent serplulimab to chemotherapy significantly boosts the overall survival of treatment-naïve individuals with extensive-stage small-cell lung cancer, according to ASTRUM-005 trial results published in JAMA.
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

More on lung cancer with driver mutations and targeted therapies

22-09-2023 | KRAS inhibitors | News

Novel KRAS inhibitor elicits ‘durable responses’ in KRAS G12C mutation-positive tumors

04-07-2023 | Non-small-cell lung cancer | News

Adagrasib shows intracranial efficacy in KRYSTAL-1 trial

06-06-2023 | Non-small-cell lung cancer | Conference coverage | News

ADAURA demonstrates OS gain with adjuvant osimertinib in early-stage NSCLC

12-01-2023 | Non-small-cell lung cancer | News

CROWN update confirms long-term lorlatinib PFS benefit
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

More on immunotherapy

13-09-2023 | Immunotherapy | News

Cutaneous irAEs tied to improved survival after ICI treatment

18-08-2023 | Non-small-cell lung cancer | News

Combining SABR with immunotherapy prolongs NSCLC event-free survival

28-07-2023 | Non-small-cell lung cancer | News

Atezolizumab may be beneficial for platinum-ineligible advanced NSCLC

15-06-2023 | Non-small-cell lung cancer | News

Interim KEYNOTE-671 findings support perioperative pembrolizumab for resectable NSCLC

25-05-2023 | Checkpoint blockade | News

Real-world data provide reassurance for ICI use in people with HIV and cancer

14-04-2023 | Lung cancer | News

Addition of ipilimumab to neoadjuvant nivolumab–chemo for NSCLC warrants further investigation
  • » This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.
Image Credits